Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing
Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.
Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.